ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1898

Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison

Evelyn Fagan1, Joseph McGrath1, Calla Sullivan1, Mackenzie Kilton1, Kaeli Samson2, Kaleb Michaud3 and Sarah Lonowski1, 1University of Nebraska Medical Center Department of Dermatology, Omaha, NE, 2University of Nebraska Medical Center Department of Biostatistics, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Dermatology, Epidemiology, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1877–1913) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational study sought to determine whether participants with psoriasis and psoriatic arthritis, enrolled in the FORWARD Psoriasis Registry, reflect the broader invited population at a single institution.

Methods: The FORWARD Psoriasis Registry is a multi-institutional, prospective U.S. study collecting patient-reported outcomes via online questionnaires.1 Patients with “psoriasis” documented in their medical record were invited to the registry via email. Enrollment status was tracked, and medical records were reviewed for demographics, comorbidities, dermatology visits, and current and past psoriasis therapies. Patients without a confirmed psoriasis diagnosis were excluded. Chi-squared, Fisher’s Exact, Wilcoxon rank sum, and equal variance t-tests were used to compare enrolled and non-enrolled groups.

Results: Of 917 patients invited, 113 enrolled (12%) and 804 (88%) did not. Enrollees were younger than non-enrollees (mean age 48.8 vs. 53.5; p=0.004), and insurance type varied significantly between groups (p=0.013). Enrollees had a higher proportion of private insurance while non-enrollees were more likely to have Medicare. Enrollees and non-enrollees did not differ across other demographic variables. Rates of obesity, hypertension, hyperlipidemia, thromboembolic events, and diabetes were not significantly different between groups. However, psoriatic arthritis was more common among enrollees (26.5% vs. 16.9%; p=0.013) (Table 1). Plaque psoriasis was the most common psoriasis phenotype among both enrollees and non-enrollees, and the proportion of those with plaque psoriasis did not vary between groups (p=0.455). The use of topical and biologic therapy did not differ between groups, though there was a significantly greater proportion of enrollees who utilized non-biologic systemic therapy in the past (34.5% vs. 24.9%; p=0.029) (Table 2).

Conclusion: Enrollees were broadly representative of those who were invited across demographic and cardiometabolic variables, though they were younger, had a higher prevalence of psoriatic arthritis, and were more likely to have tried non-biologic systemic therapy previously. This bias may reflect higher levels of participation among patients who are more comfortable with the registry’s online format and may indicate that patients with multisystem (i.e. skin and joint) disease are more motivated to participate in research registries. Overall, the study suggests findings from this institution’s FORWARD psoriasis registry can be generalized to the broader psoriasis population if these important differences are taken into account in future research.References:1. Song WB, Michaud K, Lonowski SL, et al. The forward psoriasis registry: patient-reported outcomes in a novel psoriasis registry. J Psoriasis Psoriatic Arthritis. 2024 Nov 20. doi:10.1177/24755303241303089.

Supporting image 1Table 1. Demographic Characteristics and Comorbidities in Enrolled and Invited Psoriasis FORWARD Registry Groups

Supporting image 2Table 2. Psoriasis Phenotype and Therapy Usage in Enrolled vs. Invited Psoriasis FORWARD Registry Groups


Disclosures: E. Fagan: None; J. McGrath: None; C. Sullivan: None; M. Kilton: None; K. Samson: None; K. Michaud: None; S. Lonowski: AstraZeneca, 12,, 5, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 12,, 5.

To cite this abstract in AMA style:

Fagan E, McGrath J, Sullivan C, Kilton M, Samson K, Michaud K, Lonowski S. Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/assessing-representation-in-a-nation-wide-psoriasis-registry-a-single-institution-comparison/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-representation-in-a-nation-wide-psoriasis-registry-a-single-institution-comparison/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology